SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
SurModics ( SRDX ) Q3 Earnings and Revenues Beat Estimates
SurModics (SRDX) delivered earnings and revenue surprises of +128.57% and +4.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Surmodics ( SRDX ) Q3 EPS Turns Positive
Surmodics ( NASDAQ:SRDX ) , a medical device technology firm known for its vascular intervention products and performance coatings, released results for Q3 FY2025 on August 8, 2025. The core news was a beat on both the top ( GAAP revenue ) and bottom ( non-GAAP EPS ) lines.
ICU Medical ( ICUI ) Surpasses Q2 Earnings and Revenue Estimates
ICU Medical (ICUI) delivered earnings and revenue surprises of +45.83% and +0.55%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. ( EOLS ) Reports Q2 Loss, Lags Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of -166.67% and -16.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
QuidelOrtho ( QDEL ) Down 18% Since Last Earnings Report: Can It Rebound?
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is SurModics ( SRDX ) Up 6% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Options Traders Betting on a Big Move in Surmodics Stock?
Investors need to pay close attention to SRDX stock based on the movements in the options market lately.
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.
SurModics ( SRDX ) Reports Q2 Loss, Misses Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of -116.67% and 8.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Deal Dispatch: US M&A Is Quiet But Abroad? Volume Is High - Brookfield Infrastructure ( NYSE:BIP ) , Amazon.com ( NASDAQ:AMZN )
This week's column includes updates from Hershey's, Rocket Companies, Rogers Communications and OnlyFans' Tim Stokely. Totalmobile and TIP Group could potentially be up for sale, Bloomberg reports. With stocks plunging, steady income is key.
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System
Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions.
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now
SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.
Deal Dispatch: Clock Ticks On TikTok, Raizen Explores Asset Sale, Investors Urge Walgreens To Go Private - American Express ( NYSE:AXP ) , Allegro Microsystems ( NASDAQ:ALGM )
Morgan Stanley's Michael Grimes, who helped steer the Uber IPO, is overseeing the formation of a U.S. sovereign wealth fund. Deal pros banked on looser regulations and a more vibrant stock market under Trump. Neither scenario has come to fruition.
Why Surmodics Stock Is Falling On Friday - Surmodics ( NASDAQ:SRDX )
Surmodics stock fell 4.76% after the FTC challenged its merger with GTCR due to concerns over potential competition issues. Surmodics remains committed to completing the $627M acquisition and says it will vigorously defend the case in court.
Top 3 Health Care Stocks You'll Regret Missing This Month - Radiopharm Theranostics ( NASDAQ:RADX ) , Merck & Co ( NYSE:MRK )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
SurModics ( SRDX ) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.
SurModics ( SRDX ) Reports Q1 Loss, Misses Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of 50% and 10.55%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Add Surmodics Stock to Your Portfolio Now
SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months.
After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics ( SRDX )
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SurModics ( SRDX ) Upgraded to Strong Buy: What Does It Mean for the Stock?
SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for January 3rd
UAA, BRBR, RBA, SRDX and CTRA have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
Why Is SurModics ( SRDX ) Up 4% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SurModics ( SRDX ) is an Incredible Growth Stock: 3 Reasons Why
SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
SurModics ( SRDX ) Reports Q4 Loss, Tops Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of 51.85% and 8.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ResMed ( RMD ) Surpasses Q1 Earnings and Revenue Estimates
ResMed (RMD) delivered earnings and revenue surprises of 8.37% and 2.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
SRDX Stock Down Despite FDA Clearance for Pounce XL System
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
SurModics ( SRDX ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
SurModics (SRDX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a ...
Down -5.46% in 4 Weeks, Here's Why SurModics Looks Ripe for a Turnaround - Surmodics ( NASDAQ:SRDX )
A downtrend has been apparent in SurModics SRDX lately with too much selling pressure. The stock has declined 5.5% over the past four weeks.
Down -5.46% in 4 Weeks, Here's Why SurModics ( SRDX ) Looks Ripe for a Turnaround
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SurModics Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Surmodics ( NASDAQ:SRDX )
SurModics SRDX has been on a downward spiral lately with significant selling pressure. After declining 6.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company ...
SurModics ( SRDX ) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SurModics ( SRDX ) Reports Q3 Loss, Tops Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of 12.90% and 0.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Take the Zacks Approach to Beat the Markets: Chewy, Pitney Bowes, 3M in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
StockNews.com Begins Coverage on Surmodics ( NASDAQ:SRDX )
Investment analysts at StockNews.com initiated coverage on shares of Surmodics ( NASDAQ:SRDX - Get Free Report ) in a research report issued to clients and investors on Wednesday. The firm set a "hold" rating on the stock. SRDX has been the subject of several other reports.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, SRDX, AGS, VAPO on Behalf of Shareholders - Atrion ( NASDAQ:ATRI ) , PlayAGS ( NYSE:AGS )
NEW YORK, July 08, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDX
NEW YORK, July 08, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SRDX, ATRI on Behalf of Shareholders - Alimera Sciences ( NASDAQ:ALIM ) , Atrion ( NASDAQ:ATRI )
NEW YORK, July 04, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc.
Surmodics ( NASDAQ:SRDX ) Receives New Coverage from Analysts at StockNews.com
StockNews.com began coverage on shares of Surmodics ( NASDAQ:SRDX - Get Free Report ) in a note issued to investors on Tuesday. The brokerage set a "hold" rating on the stock.
StockNews.com Initiates Coverage on Surmodics ( NASDAQ:SRDX )
Investment analysts at StockNews.com initiated coverage on shares of Surmodics ( NASDAQ:SRDX - Get Free Report ) in a note issued to investors on Monday. The firm set a "hold" rating on the stock. Other equities research analysts have also issued research reports about the company.
Surmodics ( NASDAQ:SRDX ) Receives New Coverage from Analysts at StockNews.com
Investment analysts at StockNews.com started coverage on shares of Surmodics ( NASDAQ:SRDX - Get Free Report ) in a report issued on Sunday. The brokerage set a "hold" rating on the stock. SRDX has been the subject of a number of other research reports.
Surmodics ( SRDX ) Inks Group Purchasing Agreement With Premier
Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Marathon Oil Corporation ( NYSE - MRO ) , Atrion Corporation ( Nasdaq - ATRI ) , Surmodics, Inc. ( Nasdaq - SRDX ) , Akili, Inc. ( Nasdaq - AKLI )
BALA CYNWYD, Pa., June 06, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Why Is Perrigo ( PRGO ) Down 15.1% Since Last Earnings Report?
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kuehn Law Encourages AMBC, SGRP, SRDX, and SRCL Investors to Contact Law Firm - Ambac Financial Group ( NYSE:AMBC ) , SPAR Group ( NASDAQ:SGRP )
SOUTHAMPTON, N.Y., June 05, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate SRCL, MRO, SRDX - Marathon Oil ( NYSE:MRO ) , Stericycle ( NASDAQ:SRCL )
NEW YORK, June 04, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Stericycle, Inc.
Why Is SurModics ( SRDX ) Up 21.9% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
